Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Biologics and JAK inhibitors may improve treatment for scarring alopecias.

Tacrolimus is effective for various skin conditions with fewer side effects than cyclosporine.

Certain immune cells contribute to skin autoimmune diseases, and some treatments can reverse hair loss in these conditions.

Biologic treatments for Crohn's disease and ulcerative colitis can cause skin problems, and doctors should adjust treatment if these occur.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

Etanercept, a psoriasis treatment, caused hair loss in a patient.

Ocrelizumab helped control lupus in a pregnant patient, leading to the birth of a healthy baby.

Methotrexate is a promising and safe treatment for severe alopecia areata, with better results when combined with corticosteroids.

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

Rebamipide may help regrow hair by activating hair follicle stem cells.

Ruxolitinib cream may help treat severe hair loss in children.

Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.

Mogamulizumab can cause hair loss and skin rashes.

Methotrexate with steroids is slightly more effective than azathioprine with steroids for treating severe alopecia areata.

Combining mesotherapy with systemic treatments effectively improves alopecia universalis treatment.

A mother and son both had ulcerative colitis and alopecia, suggesting a genetic link in autoimmune disorders and successful treatment with cyclosporine.

A new hydrogel treatment reduces inflammation and promotes hair growth in alopecia areata.

A new hydrogel treatment reduces inflammation and promotes hair growth in alopecia areata.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.

ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Using the drugs AMD3100 and Tacrolimus together greatly improves skin healing and hair growth after a deep skin cut by increasing stem cells in the wound.

Platelet-rich Plasma Gel may help treat en coup de sabre scleroderma, improving symptoms and skin quality with minimal side effects.

A microneedle patch can help regrow hair by restoring immune balance in hair follicles.

CS12192 effectively treats alopecia areata with better safety than current options.

Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.